Japanese Record-Breaking Anime Blockbuster Film EVANGELION:3.0+1.01 THRICE UPON A TIME to Launch Exclusively on Amazon Prime Video on August 13th
1.7.2021 18:35:00 EEST | Business Wire | Press release
Amazon Prime Video today announced the exclusive global premiere (outside of Japan) of the highly anticipated Japanese anime blockbuster EVANGELION:3.0+1.01 THRICE UPON A TIME on August 13th. EVANGELION:3.0+1.01 THRICE UPON A TIME is the fourth and final chapter of the new theatrical edition of Evangelion. The anime film – which is the highest-grossing in all movies by chief director Hideaki Anno and most-watched movie in Japanese theatres in 2021- is from directors Kazuya Tsurumaki, Katsuichi Nakayama and Mahiro Maeda as well as legendary creator, screenwriter and chief director Hideaki Anno (Shin Godzilla). To celebrate the finale of the franchise, Prime Video will also release the three previous movies, EVANGELION:1.11 YOU ARE (NOT) ALONE., EVANGELION:2.22 YOU CAN (NOT) ADVANCE., EVANGELION:3.33 YOU CAN (NOT) REDO. to fans in more than 240 countries and territories.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005692/en/
Japanese Record-Breaking Anime Blockbuster Film EVANGELION:3.0+1.01 THRICE UPON A TIME to Launch Exclusively on Amazon Prime Video on August 13th (Graphic: Business Wire)
The blockbuster franchise is a Japanese anime pop culture phenomenon based on the story of Evangelion, an artificial human and multipurpose humanoid weapon, and the Angels, an unknown life-form which takes place after the Earth has been shattered by a cataclysmic event. The film features all original voice actors including Megumi Ogata, Megumi Hayashibara, Yûko Miyamura and uses the latest imaging technology to showcase the personalities and relationships of its unique characters as they fight for survival. It will be dubbed in 10 languages including English, French, German, Portuguese, Spanish and Italian, and offer subtitles in 28 languages.
Since the TV series first aired in 1995, the Evangelion franchise has had a significant impact on Japanese pop culture and has elevated the anime genre worldwide. The legendary anime franchise was then reborn as a new movie series Evangelion: New Theatrical Edition in 2007 and this fourth and final movie released across theatres in Japan in March has gone on to break records, both for Hideaki Anno’s films and also as Japan’s most-watched theatrical movie of the year. EVANGELION:3.0+1.01 THRICE UPON A TIME on Amazon Prime Video will be the latest version of the film which includes revised scenes and is releasing across theatres now in Japan.
“The EVANGELION films have been thrilling fans for years and we know that there is a huge appetite around the world for the finale,” said Brad Beale, Vice President, Worldwide Content Licensing Prime Video. “I’m excited for Prime members worldwide to finally have the opportunity to watch the anime masterpiece EVANGELION:3.0+1.01 THRICE UPON A TIME, as well as the three previous films.”
“I’d like to thank every Eva fan in the world for your continued support,” said Hideaki Anno, Creator, Screenwriter and Chief Director. “We were looking for the best way to offer the movie to fans overseas as early as possible in a challenging situation with movie theatres during COVID-19, and are happy to have found Prime Video as a partner to stream it globally. We highly recommend watching it on a big TV screen for the best viewing experience.”
ABOUT
EVANGELION:3.0+1.01 THRICE UPON A TIME
The fourth and final installment of the Rebuild of Evangelion. Misato and her anti-Nerv group Wille arrive in Paris, a city now red from core-ization. Crew from the flagship Wunder land on a containment tower. They only have 720 seconds to restore the city. When a horde of Nerv Evas appear, Mari’s improved Eva Unit 8 must intercept. Meanwhile, Shinji, Asuka, and Rei (provisional name) wander around Japan.
Studio: khara, Inc.
Chief director: Hideaki Anno, Director: Kazuya Tsurumaki, Katsuichi Nakayama and Mahiro Maeda, Screenwriter: Hideaki Anno
ABOUT THE THREE PREVIOUS MOVIES
EVANGELION:1.11 YOU ARE (NOT) ALONE.
Scarred by the Second Impact, the Fourth Angel attacks Tokyo III and humanity's fate is left in the hands of Special Government Agency Nerv. Young Shinji Ikari is forced to pilot EVA-01. He and EVA-00 pilot Rei Ayanami are tasked to fight, but EVA-01 is damaged by the Sixth Angel. Misato Katsuragi draws up a plan to focus all of Japan's electricity into EVA-01's positron cannon to defeat the Angel.
Studio: khara, Inc.
Chief director: Hideaki Anno, Director: Masayuki and Kazuya Tsurumaki, Screenwriter: Hideaki Anno
EVANGELION:2.22 YOU CAN (NOT) ADVANCE.
Mari Illustrious-Makinami pilots Provisional Unit-05 to defeat the excavated Third Angel. Asuka Langley-Shikinami and EVA-02 defeat the Seventh Angel. The Eighth Angel appears and attacks Nerv HQ. EVA-03 is taken over by the Ninth Angel during testing and Shinji deploys to stop it, but learns Asuka is aboard. Gendo switches EVA-01's controls over to the Dummy System and begins fighting EVA-03.
Studio: khara, Inc.
Chief director: Hideaki Anno, Director: Masayuki and Kazuya Tsurumaki, Screenwriter: Hideaki Anno
EVANGELION:3.33 YOU CAN (NOT) REDO.
Shinji wakes after 14 years aboard the battleship AAA Wunder belonging to an anti-Nerv organization founded by former Nerv members. Shinji hears Rei's voice coming from EVA Mark.09, sent to rescue him, so he leaves Wunder and heads to Nerv. Kaworu Nagisa shows Shinji the transformed land. He learns that saving Rei triggered the Near Third Impact that caused the catastrophic damage to Earth.
Studio: khara, Inc.
Chief director: Hideaki Anno, Director: Masayuki, Mahiro Maeda and Kazuya Tsurumaki, Screenwriter: Hideaki Anno
EVANGELION:3.0+1.01 THRICE UPON A TIME will join the thousands of TV shows and movies in the Prime Video catalogue, including award-winning and critically acclaimed global Amazon Originals like Borat Subsequent Moviefilm, Tom Clancy's Jack Ryan, The Boys, Hunters, Fleabag, and The Marvelous Mrs. Maisel. All this is available on Prime Video at no extra cost for Prime members. Prime members will be able to watch EVANGELION:3.0+1.01 THRICE UPON A TIME anywhere and anytime on the Prime Video app for smart TVs, mobile devices, Fire TV, Fire TV stick, Fire tablets, Apple TV, and stream online. In the Prime Video app, Prime members can download episodes on their mobile devices and tablets and watch anywhere offline.
Amazon
Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005692/en/
Contact information
Press Contacts for Prime Video & Amazon Studios:
Arianne Rocchi: roccha@amazon.com
Ayumi Sakaguchi: ayusaka@amazon.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom